Swiss drug maker NovImmune has begun a proof-of-concept study to evaluate NI-0801 in patients with primary biliary cirrhosis.

NI-0801 is a fully human monoclonal antibody that neutralises CXCL10 / interferon-gamma-inducible protein-10 (IP-10) chemokine.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

Two previous Phase I trials have demonstrated that the drug is safe and well tolerated when given to healthy volunteers.

Principal investigator David Adams said that the therapeutic approach of neutralising CXCL10 / IP-10 with NI-0801 will offer great benefits to the large and therapeutically ill-served primary biliary cirrhosis patient population.

Pharmaceutical Technology Excellence Awards - The Benefits of Entering

Gain the recognition you deserve! The Pharmaceutical Technology Excellence Awards celebrate innovation, leadership, and impact. By entering, you showcase your achievements, elevate your industry profile, and position yourself among top leaders driving pharmaceutical advancements. Don’t miss your chance to stand out—submit your entry today!

Nominate Now